| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Novavax has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Novavax, Inc. | 41 |
$65 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Novavax Inc | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | NOVAVAX INC (NVAX=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | NOVAVAX INC (NVAX=US) 2-weeks forecast | 1 |
$10 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: NOVAVAX -- NVAX | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: BPAX , CYTX , MNTA , NVAX , TTNP , TRMS , XNPT -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | NOVAVAX INC (NVAX=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Nanotechnology & MEMS Industry Trends, Statistics & Analysis 2009 (Summary) | 34 |
$199 |
1.48% Nasdaq 
Research Reports
